Tolerance and Effectiveness of Targeted Therapies in Aged Patients with Metastatic Melanoma.
Fiche publication
Date publication
juin 2021
Journal
Cancers
Auteurs
Membres identifiés du Cancéropôle Est :
Pr AUBIN François, Dr DALAC Sophie
Tous les auteurs :
Becquart O, Oriano B, Dalle S, Mortier L, Leccia MT, Dutriaux C, Dalac S, Montaudié H, De Quatrebarbes J, Brunet-Possenti F, Saiag P, Lesimple T, Beylot-Barry M, Aubin F, Stoebner PE, Arnault JP, Dreno B, Porcher R, Lebbe C, Guillot B
Lien Pubmed
Résumé
Melanoma's incidence is increasing, and elderly people could be significantly impacted since the majority occurs in people over 65 years of age. Combined BRAF and MEK targeted therapies (TT) are current standard regimen for BRAF mutated metastatic melanoma (MM). Except for subgroups of pivotal trials, little data are available for TT in this population.
Mots clés
elderly people, melanoma, side effects, targeted therapy
Référence
Cancers (Basel). 2021 Jun 18;13(12):